Clinical Read2026-06-30
NTX-253 (Muscarinic M4 PAM)
Addex TherapeuticsADXN
- Indication
- Schizophrenia
- Stage
- Phase 1
- Event
- Phase 1 Data readout
- Details
04/23/26:- Phase 1 SAD/MAD study for NTX-253 is expected to complete in Q2 2026.
Financial Snapshot
Market Cap
$7.4M
Price
$6.23